Drug repurposing against COVID-19: focus on anticancer agents

BACKGROUND: The very limited time allowed to face the COVID-19 pandemic poses a pressing challenge to find proper therapeutic approaches. However, synthesis and full investigation from preclinical studies to phase III trials of new medications is a time-consuming procedure, and not viable in a globa...

Descripción completa

Detalles Bibliográficos
Autores principales: Ciliberto, Gennaro, Mancini, Rita, Paggi, Marco G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7214852/
https://www.ncbi.nlm.nih.gov/pubmed/32398164
http://dx.doi.org/10.1186/s13046-020-01590-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7214852/
https://www.ncbi.nlm.nih.gov/pubmed/32398164
http://dx.doi.org/10.1186/s13046-020-01590-2

Ejemplares similares